Developer docs
API playgroundTry for free, no card

Search company profiles

Mesh Bio

Full company profile

uuid00059bj

Namestring
Mesh Bio
Legal namestring
Mesh Bio Pte. Ltd.
Websiteurl
meshbio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Mesh Bio is a Singapore-headquartered digital health company founded in 2018 by Andrew Wu (CEO) and Arsen Batagov (CTO). The company develops AI-powered predictive analytics software for chronic disease management, with its core DARA® platform automating health screening workflows, generating risk-stratified clinical reports, and integrating into hospital electronic health record systems via Epic and FHIR/HL7 standards. Underlying the platform is a proprietary digital twin technology that uses metabolic flux analysis to model patient-level disease trajectories and is validated across 7,000+ clinical scenarios against datasets such as the SingHealth Diabetes Registry and the NHG Chronic Disease Management Datamart.

The company has expanded into regulated medical devices with HealthVector® Diabetes, an HSA-approved Class B Software as a Medical Device that predicts 3-year chronic kidney disease risk in Type 2 diabetes patients. Mesh Bio sells primarily to enterprise healthcare providers — hospitals, health screening centers, clinics, and diagnostic laboratories — through direct enterprise sales on a subscription SaaS model, supplemented by implementation pilots funded in part by Singapore's National Health Innovation Centre (NHIC). The company reports 40+ healthcare group customers and 300,000+ patients assessed across Singapore, Indonesia, Malaysia, the Philippines, and Hong Kong, with named enterprise accounts including Parkway Shenton, Fullerton Health, PT Pramita, Singapore General Hospital, and Tan Tock Seng Hospital.

Mesh Bio holds ISO 27001 (information security) and ISO 13485 (medical device quality management) certifications and has raised approximately $5.3 million in disclosed funding across a 2021 seed round, a 2023 East Ventures investment, and a $3.5 million Series A in January 2024, with backers including East Ventures, Elev8.vc, Seeds Capital, Citrine Capital, and Tael Partners. The business model combines subscription software licensing for DARA with regulated-device commercialization via HealthVector Diabetes, positioning the company at the intersection of enterprise health IT and clinical decision support across Southeast Asia.

Short descriptiontext

Singapore-headquartered digital health company founded in 2018 that builds AI-powered digital twin predictive analytics for chronic disease management, selling its DARA platform and HSA-cleared HealthVector Diabetes SaMD to hospitals, clinics, and laboratories across Southeast Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
predictive health analytics, chronic disease management, clinical decision support, digital twin technology, health screening automation
Industry2 codes
PRIMARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAPAD
Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code2 codes
  • Software Publishers5132
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Health Services8000
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Health Analytics Software
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Software/SaaS Subscription
TypeSubscription Recurring
Description

Mesh Bio provides AI-powered health analytics software to healthcare providers on a subscription basis. The platform is deployed at healthcare groups across Asia, with pricing likely structured around the number of patients assessed or healthcare providers served.

meshbio.com
2Regulatory-approved Medical Device
TypeSubscription Recurring
Description

HealthVector Diabetes is approved as a Class B Software as a Medical Device (SaMD) by HSA Singapore, allowing deployment in clinical settings with regulatory compliance.

meshbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise B2B pricing for healthcare providers
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed. Direct sales approach with demo booking indicates custom enterprise pricing based on healthcare group size and patient volume.

meshbio.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1DARA
Description

Predictive analytics and clinical workflow automation solution for healthcare providers featuring automated health screening reports, risk stratification, clinical decision support, and integration with existing workflows

meshbio.com
+1 more record
Core offering1 text field

Mesh Bio sells an AI-powered health intelligence software platform called DARA® that delivers predictive analytics, risk stratification, and clinical workflow automation to healthcare providers for chronic disease management. The company also offers HealthVector® Diabetes, an HSA-approved Class B Software as a Medical Device that predicts 3-year onset risk of chronic kidney disease in Type 2 diabetes patients using metabolic digital twin technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduce manual report generation by 90%
+4 more records
Product overview1 text field

Mesh Bio's product portfolio is organised as a platform-plus-modules architecture. The flagship platform is DARA® (Health Intelligence Platform), which provides predictive analytics and clinical workflow automation for healthcare providers. DARA® comprises three integrated modules: the Health Screening Module (automated report generation and risk scoring), the Result Interpretation Module (digitised specialist result workflows), and the Referral Module (digital referral management with tracking). The HealthVector® Diabetes sub-brand is a regulatory-approved (HSA Class B SaMD) digital twin product for predicting 3-year CKD risk in Type 2 diabetes patients, which also operates as a standalone module within the DARA® ecosystem. The platform collectively covers chronic diseases including diabetes, cardiovascular disease, hypertension, chronic kidney disease, and MAFLD, and is deployed across Singapore, Malaysia, Hong Kong, and Indonesia.

Product and service5 records
1DARA® Health Intelligence Platform
CategoryHealth intelligence / clinical decision support software
Description

DARA® is the core health intelligence platform providing predictive analytics and clinical workflow automation for healthcare providers, supporting health screening, result interpretation, and referral management. It generates automated personalised clinical reports, performs risk stratification across cardiovascular disease, diabetes, hypertension, chronic kidney disease, and MAFLD using a portfolio of clinically validated risk calculators covering 7,000+ clinical scenarios, and provides clinical decision support integrated with existing workflows and EHR systems. Target users are hospitals, health screening centres, polyclinics, and diagnostic laboratories across Asia.

2DARA® Health Screening
CategoryHealth screening automation software
Description

Automates health screening reports and risk analysis for primary care providers, health screening centres, and hospitals. The module generates complete reports in under 20 seconds with predictive analytics covering multiple chronic diseases, including cardiovascular disease, diabetes, hypertension, chronic kidney disease, and MAFLD, and supports risk projection up to 10 years before clinical diagnosis.

3DARA® Result Interpretation
CategoryClinical workflow automation software
Description

Digitises the result interpretation workflow for specialists, replacing manual processes such as printing, scanning, emailing, faxing, and courier delivery of results. Features include prioritisation of requests, physician notes integration, DRP and treadmill test interpretation, and real-time status tracking. Target users are specialist physicians and diagnostic laboratories handling high volumes of test results.

4DARA® Referral
CategoryClinical workflow automation software
Description

Digitises the referral workflow between clinics and specialists, enabling digital referral letter preparation, specialist request routing by network or insurance panel, referral progress tracking in real time, and secured sharing of consented patient health data. Target users are primary care clinics and specialist networks managing inter-provider referrals.

5HealthVector® Diabetes
CategorySoftware as a Medical Device (SaMD) — predictive analytics
Description

A regulatory-approved (HSA Class B SaMD) digital twin analysis software that provides a 3-year risk estimate for chronic kidney disease (CKD) stage 3A+ in adult patients aged 20-80 with Type 2 diabetes, using metabolic flux analysis and mechanistic physiological modelling without requiring specialised testing. Target users are endocrinologists, nephrologists, internal medicine specialists, and hospitals managing large Type 2 diabetes populations.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-26
Description

Implementation pilot for HealthVector Diabetes at Singapore General Hospital for potential clinical adoption. Validation study led by SGH using SingHealth Diabetes Registry dataset.

2Tan Tock Seng Hospital (TTSH)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-26
Description

Implementation pilot for HealthVector Diabetes at Tan Tock Seng Hospital with Associate Professor Rinkoo Dalan co-leading research study. Supported by NHIC I2Adopt Grant.

meshbio.com
3National Healthcare Group (NHG) Centre for Medical Technologies and Innovations (CMTi)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-10-26
Description

NHG CMTi facilitated partnership between Mesh Bio and TTSH for HealthVector Diabetes implementation pilot.

meshbio.com
4PT Pramita
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-17
Description

MOU signed for adoption of Mesh Bio's predictive analytics software across more than 30 diagnostic centers in Indonesia. Partnership aims to deliver personalized preventive care and disease risk insights.

meshbio.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-06-30
Description

Partnership to conduct observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease. UK-based AI-enabled drug discovery company.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-11-19
Description

Mesh Bio became the first Asian start-up to join Startup Creasphere Batch 3 accelerator program, an international collaboration to pilot digital solutions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based AI chronic disease prevention and management platform for diabetes, hypertension, and prediabetes. Direct peer: comparable AI-driven chronic-disease prediction platform, enterprise/payer GTM.

TypeDirect peer
Description

US-based virtual care company using predictive analytics and digital coaching for diabetes, hypertension, and chronic disease prevention. Direct peer: same chronic-disease predictive analytics + virtual care model, employer/payer/provider GTM.

TypeDirect peer
Description

US-based digital therapeutics platform focused on diabetes and cardiovascular chronic disease management using AI-driven coaching and analytics. Direct peer: similar diabetes/CVD focus, regulated SaMD positioning (FDA-cleared), enterprise B2B GTM.

4Tempus AI
TypeBroad incumbent
Description

US AI-driven precision medicine company applying AI to clinical and molecular data for disease prediction, diagnostics, and pharma research. Broad incumbent: comparable AI analytics for chronic disease + pharma/biomarker focus, but at much larger scale.

TypeDirect peer
Description

Diabetes data management and analytics platform integrating devices and EHRs for clinicians and patients. Direct peer: comparable diabetes-focused SaaS with EHR integration, similar provider-and-patient analytics play.

TypeBroad incumbent
Description

Alphabet-owned precision health company applying AI, digital twins, and real-world evidence to chronic disease research and care. Broad incumbent: deeper pockets, broader portfolio, but overlapping chronic-disease + digital-twin thesis with global scale.

7Doctor Anywhere
TypeRegional player
Description

Singapore-headquartered regional telehealth and chronic care platform serving Southeast Asia. Regional peer: same Singapore base and SEA healthcare provider market, overlapping chronic-disease management themes though delivered more via telehealth than analytics-first.

8Biofourmis
TypeDirect peer
Description

Boston/Singapore-based AI health company focused on remote patient monitoring and predictive analytics for chronic conditions (heart failure, COPD, diabetes). Direct peer: same AI-driven chronic-disease prediction thesis, similar Southeast Asia presence, comparable enterprise provider and pharma customers.

TypeDirect peer
Description

Singapore-headquartered digital health company building a behavioral health and chronic disease analytics platform using real-world clinical data. Direct peer: overlapping chronic-disease analytics category, similar Singapore/SEA base, comparable B2B SaaS model aimed at providers and pharma.

TypeDirect peer
Description

Global digital therapeutics company focused on diabetes, hypertension, and musculoskeletal chronic conditions. Direct peer: similar diabetes/CKD/chronic disease focus, B2B2C SaaS distribution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mesh Bio

Digital Health Analytics Softwaremeshbio.com

Singapore-headquartered digital health company founded in 2018 that builds AI-powered digital twin predictive analytics for chronic disease management, selling its DARA platform and HSA-cleared HealthVector Diabetes SaMD to hospitals, clinics, and laboratories across Southeast Asia.

What Mesh Bio does

Mesh Bio is a Singapore-headquartered digital health company founded in 2018 by Andrew Wu (CEO) and Arsen Batagov (CTO). The company develops AI-powered predictive analytics software for chronic disease management, with its core DARA® platform automating health screening workflows, generating risk-stratified clinical reports, and integrating into hospital electronic health record systems via Epic and FHIR/HL7 standards. Underlying the platform is a proprietary digital twin technology that uses metabolic flux analysis to model patient-level disease trajectories and is validated across 7,000+ clinical scenarios against datasets such as the SingHealth Diabetes Registry and the NHG Chronic Disease Management Datamart.

The company has expanded into regulated medical devices with HealthVector® Diabetes, an HSA-approved Class B Software as a Medical Device that predicts 3-year chronic kidney disease risk in Type 2 diabetes patients. Mesh Bio sells primarily to enterprise healthcare providers — hospitals, health screening centers, clinics, and diagnostic laboratories — through direct enterprise sales on a subscription SaaS model, supplemented by implementation pilots funded in part by Singapore's National Health Innovation Centre (NHIC). The company reports 40+ healthcare group customers and 300,000+ patients assessed across Singapore, Indonesia, Malaysia, the Philippines, and Hong Kong, with named enterprise accounts including Parkway Shenton, Fullerton Health, PT Pramita, Singapore General Hospital, and Tan Tock Seng Hospital.

Mesh Bio holds ISO 27001 (information security) and ISO 13485 (medical device quality management) certifications and has raised approximately $5.3 million in disclosed funding across a 2021 seed round, a 2023 East Ventures investment, and a $3.5 million Series A in January 2024, with backers including East Ventures, Elev8.vc, Seeds Capital, Citrine Capital, and Tael Partners. The business model combines subscription software licensing for DARA with regulated-device commercialization via HealthVector Diabetes, positioning the company at the intersection of enterprise health IT and clinical decision support across Southeast Asia.

Mesh Bio firmographics

Firmographics
Name
Mesh Bio
Legal name
Mesh Bio Pte. Ltd.
Website
https://meshbio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Singapore-headquartered digital health company founded in 2018 that builds AI-powered digital twin predictive analytics for chronic disease management, selling its DARA platform and HSA-cleared HealthVector Diabetes SaMD to hospitals, clinics, and laboratories across Southeast Asia.
Ownership category
akta.pro rank

Mesh Bio industry classification

Industry
Product category
Digital Health Analytics Software
NAICS
Software Publishers (5132), Computer Systems Design and Related Services (54151)
SIC
Services-Health Services (8000), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAPAD
Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Predictive health analytics
  • Chronic disease management
  • Clinical decision support
  • Digital twin technology
  • Health screening automation

Where Mesh Bio is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

Mesh Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Software/SaaS Subscription: Mesh Bio provides AI-powered health analytics software to healthcare providers on a subscription basis. The platform is deployed at healthcare groups across Asia, with pricing likely structured around the number of patients assessed or healthcare providers served.
  2. Regulatory-approved Medical Device: HealthVector Diabetes is approved as a Class B Software as a Medical Device (SaMD) by HSA Singapore, allowing deployment in clinical settings with regulatory compliance.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise B2B pricing for healthcare providers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Mesh Bio product offering

Product offering

Core offering

Mesh Bio sells an AI-powered health intelligence software platform called DARA® that delivers predictive analytics, risk stratification, and clinical workflow automation to healthcare providers for chronic disease management. The company also offers HealthVector® Diabetes, an HSA-approved Class B Software as a Medical Device that predicts 3-year onset risk of chronic kidney disease in Type 2 diabetes patients using metabolic digital twin technology.

Product overview

Mesh Bio's product portfolio is organised as a platform-plus-modules architecture. The flagship platform is DARA® (Health Intelligence Platform), which provides predictive analytics and clinical workflow automation for healthcare providers. DARA® comprises three integrated modules: the Health Screening Module (automated report generation and risk scoring), the Result Interpretation Module (digitised specialist result workflows), and the Referral Module (digital referral management with tracking). The HealthVector® Diabetes sub-brand is a regulatory-approved (HSA Class B SaMD) digital twin product for predicting 3-year CKD risk in Type 2 diabetes patients, which also operates as a standalone module within the DARA® ecosystem. The platform collectively covers chronic diseases including diabetes, cardiovascular disease, hypertension, chronic kidney disease, and MAFLD, and is deployed across Singapore, Malaysia, Hong Kong, and Indonesia.

Differentiator

Problem solved

Functional benefit

Brands

  • DARA: Predictive analytics and clinical workflow automation solution for healthcare providers featuring automated health screening reports, risk stratification, clinical decision support, and integration with existing workflows
  • HealthVector Diabetes

Products and services

  • DARA® Health Intelligence Platform DARA® is the core health intelligence platform providing predictive analytics and clinical workflow automation for healthcare providers, supporting health screening, result interpretation, and referral management. It generates automated personalised clinical reports, performs risk stratification across cardiovascular disease, diabetes, hypertension, chronic kidney disease, and MAFLD using a portfolio of clinically validated risk calculators covering 7,000+ clinical scenarios, and provides clinical decision support integrated with existing workflows and EHR systems. Target users are hospitals, health screening centres, polyclinics, and diagnostic laboratories across Asia.
  • DARA® Health Screening Automates health screening reports and risk analysis for primary care providers, health screening centres, and hospitals. The module generates complete reports in under 20 seconds with predictive analytics covering multiple chronic diseases, including cardiovascular disease, diabetes, hypertension, chronic kidney disease, and MAFLD, and supports risk projection up to 10 years before clinical diagnosis.
  • DARA® Result Interpretation Digitises the result interpretation workflow for specialists, replacing manual processes such as printing, scanning, emailing, faxing, and courier delivery of results. Features include prioritisation of requests, physician notes integration, DRP and treadmill test interpretation, and real-time status tracking. Target users are specialist physicians and diagnostic laboratories handling high volumes of test results.
  • DARA® Referral Digitises the referral workflow between clinics and specialists, enabling digital referral letter preparation, specialist request routing by network or insurance panel, referral progress tracking in real time, and secured sharing of consented patient health data. Target users are primary care clinics and specialist networks managing inter-provider referrals.
  • HealthVector® Diabetes A regulatory-approved (HSA Class B SaMD) digital twin analysis software that provides a 3-year risk estimate for chronic kidney disease (CKD) stage 3A+ in adult patients aged 20-80 with Type 2 diabetes, using metabolic flux analysis and mechanistic physiological modelling without requiring specialised testing. Target users are endocrinologists, nephrologists, internal medicine specialists, and hospitals managing large Type 2 diabetes populations.

Quantifiable outcome

  • Reduce manual report generation by 90%
  • +4 more outcomes

Companies that use Mesh Bio

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Mesh Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature5 records

Mesh Bio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, strategic and minor.

  • Singapore General Hospital (SGH)coreStrategic or Co-development Partner · 26 October 2023Implementation pilot for HealthVector Diabetes at Singapore General Hospital for potential clinical adoption. Validation study led by SGH using SingHealth Diabetes Registry dataset.
  • Tan Tock Seng Hospital (TTSH)coreStrategic or Co-development Partner · 26 October 2023Implementation pilot for HealthVector Diabetes at Tan Tock Seng Hospital with Associate Professor Rinkoo Dalan co-leading research study. Supported by NHIC I2Adopt Grant.
  • National Healthcare Group (NHG) Centre for Medical Technologies and Innovations (CMTi)strategicStrategic or Co-development Partner · 26 October 2023NHG CMTi facilitated partnership between Mesh Bio and TTSH for HealthVector Diabetes implementation pilot.
  • PT PramitacoreStrategic or Co-development Partner · 17 March 2023MOU signed for adoption of Mesh Bio's predictive analytics software across more than 30 diagnostic centers in Indonesia. Partnership aims to deliver personalized preventive care and disease risk insights.
  • MultiOmic HealthstrategicStrategic or Co-development Partner · 30 June 2022Partnership to conduct observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease. UK-based AI-enabled drug discovery company.
  • Startup CreasphereminorStrategic or Co-development Partner · 19 November 2019Mesh Bio became the first Asian start-up to join Startup Creasphere Batch 3 accelerator program, an international collaboration to pilot digital solutions.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Mesh Bio competitors and assessment

Company assessment

Direct peers

  • Lark Health: US-based AI chronic disease prevention and management platform for diabetes, hypertension, and prediabetes. Direct peer: comparable AI-driven chronic-disease prediction platform, enterprise/payer GTM.
  • Omada Health: US-based virtual care company using predictive analytics and digital coaching for diabetes, hypertension, and chronic disease prevention. Direct peer: same chronic-disease predictive analytics + virtual care model, employer/payer/provider GTM.
  • WellDoc: US-based digital therapeutics platform focused on diabetes and cardiovascular chronic disease management using AI-driven coaching and analytics. Direct peer: similar diabetes/CVD focus, regulated SaMD positioning (FDA-cleared), enterprise B2B GTM.
  • Glooko: Diabetes data management and analytics platform integrating devices and EHRs for clinicians and patients. Direct peer: comparable diabetes-focused SaaS with EHR integration, similar provider-and-patient analytics play.
  • Biofourmis: Boston/Singapore-based AI health company focused on remote patient monitoring and predictive analytics for chronic conditions (heart failure, COPD, diabetes). Direct peer: same AI-driven chronic-disease prediction thesis, similar Southeast Asia presence, comparable enterprise provider and pharma customers.
  • Holmusk: Singapore-headquartered digital health company building a behavioral health and chronic disease analytics platform using real-world clinical data. Direct peer: overlapping chronic-disease analytics category, similar Singapore/SEA base, comparable B2B SaaS model aimed at providers and pharma.
  • DarioHealth: Global digital therapeutics company focused on diabetes, hypertension, and musculoskeletal chronic conditions. Direct peer: similar diabetes/CKD/chronic disease focus, B2B2C SaaS distribution.

Broad incumbents

  • Tempus AI: US AI-driven precision medicine company applying AI to clinical and molecular data for disease prediction, diagnostics, and pharma research. Broad incumbent: comparable AI analytics for chronic disease + pharma/biomarker focus, but at much larger scale.
  • Verily (Alphabet): Alphabet-owned precision health company applying AI, digital twins, and real-world evidence to chronic disease research and care. Broad incumbent: deeper pockets, broader portfolio, but overlapping chronic-disease + digital-twin thesis with global scale.

Regional players

  • Doctor Anywhere: Singapore-headquartered regional telehealth and chronic care platform serving Southeast Asia. Regional peer: same Singapore base and SEA healthcare provider market, overlapping chronic-disease management themes though delivered more via telehealth than analytics-first.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Mesh Bio social profiles

Digital presence

Mesh Bio compliance and trust

Trust signal

Compliance3 records

Mesh Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mesh Bio leadership team

Management profile

Number of profiles

Profiles13 records

Mesh Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mesh Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mesh Bio

What does Mesh Bio do?

Mesh Bio sells an AI-powered health intelligence software platform called DARA® that delivers predictive analytics, risk stratification, and clinical workflow automation to healthcare providers for chronic disease management. The company also offers HealthVector® Diabetes, an HSA-approved Class B Software as a Medical Device that predicts 3-year onset risk of chronic kidney disease in Type 2 diabetes patients using metabolic digital twin technology.

Is Mesh Bio a public or private company?

Mesh Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mesh Bio founded?

Mesh Bio was founded in 2018. It employs 11 to 50 people.

Where is Mesh Bio based?

Mesh Bio is headquartered in Singapore, Singapore, in the Asia region.

How does Mesh Bio make money?

Two revenue lines are on record. Software/SaaS Subscription is the primary driver. The others are regulatory-approved Medical Device.

Who are Mesh Bio's main competitors?

Direct peers on record are Lark Health, Omada Health, WellDoc, Glooko, Biofourmis, Holmusk and DarioHealth. Broad incumbents are Tempus AI and Verily (Alphabet). Doctor Anywhere is listed as a regional player.

Does Mesh Bio have an API?

No public API is recorded for Mesh Bio.

What industry is Mesh Bio in?

Mesh Bio's product category is Digital Health Analytics Software. Its primary akta.pro industry code is HLACAFAM, AI/Analytics for RPM (Risk Stratification, Alerts, Predictive), with a secondary code of HLACAPAD, Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension). Its NAICS code is 5132 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SelvedgeventureAI-Driven Clinical Patient Triage – Selvedge VentureMesh Bio is developing AI-enabled clinical software designed to translate clinical data into actionable insights for patient health management. The company's first product, which assists general practitioners in health screening, is currently in use at seven medical practices in Singapore. Mesh Bio is also collaborating with medical schools and research institutes to create predictive analytics for treating diabetes and metabolic syndrome conditions.ForbesDouble Take: This Singapore Healthtech Startup Develops ‘Digital Twins’ To Manage Chronic DiseasesMesh Bio, a Singapore-based healthtech startup, raised $3.5 million in a Series A round led by East Ventures. The funding will support its digital twin technology, which creates virtual models of patients' health states based on their data.LinkedInMesh Bio raises US$3.5 million of Series A funding led by East Ventures, to make its digital twin technologies available at scaleMesh Bio announced it has raised a $3.5 million Series A round led by East Ventures, with continued backing from elev8.vc, SEEDS Capital, Selvedge Venture and other existing shareholders. The company said the funding will scale its reach and expand opportunities for its HealthVector foundational digital twin model. No financial terms or timeline were disclosed.IncubeesHealth deep-tech Mesh Bio raised $3.5 M Series A funding from VC firm East Ventures – IncubeesSingapore-based health deep-tech startup Mesh Bio has raised $3.5 million in a Series A funding round led by East Ventures, with participation from Elev8 and Seed Capital. The company plans to use the capital to expand its digital twin technology deployment for chronic disease management across Southeast Asia, including Indonesia, the Philippines, and Hong Kong. This expansion follows historic regulatory approval from Singapore’s Health Sciences Authority for its HealthVector® Diabetes software medical device.The Business TimesClearer adoption pathways needed for healthtech startups to scale in AsiaHealthtech startups in Asia face significant challenges scaling domestically due to the need for regulatory approval and clinical validation from healthcare providers, governments, and insurers. An example of this process is Mesh Bio, which is collaborating with Tan Tock Seng Hospital to quantify the cost of kidney disease to demonstrate its solution's value.IncubeesHealth deep tech startup Mesh Bio received undisclosed funding from East Ventures – IncubeesSingapore-based health deep tech startup Mesh Bio has received undisclosed funding from venture capital firm East Ventures. The company plans to use the investment to expand its digital twin technologies for chronic disease management across Southeast Asia, specifically in Indonesia, Malaysia, and the Philippines.East VenturesMesh Bio, a health deep tech startup, secured investment from East VenturesSingapore-based health deep tech startup Mesh Bio secured undisclosed funding from East Ventures to develop digital twin technologies for chronic disease management. The investment will support the expansion of its services across Southeast Asia, specifically targeting Indonesia, Malaysia, and the Philippines.KrASIADeals in brief: East Ventures invests in Mesh Bio, MoneyHero Group completes SPAC merger, multiple China and India deals, and moreThis article is a weekly roundup of venture capital and corporate finance deals across Southeast Asia, China, and India. It highlights major transactions including MoneyHero Group's SPAC merger with Bridgetown Holdings and Masdar's USD 8 billion investment agreement in Malaysia's renewable energy sector. The report also details numerous funding rounds for startups such as Mesh Bio, Account Labs, and various companies in the Chinese and Indian markets.MobiHealthNewsMesh Bio, MultiOmic Health to generate AI-driven insights on Asian metabolic diseasesSingaporean health tech startup Mesh Bio and UK-based drug discovery firm MultiOmic Health have launched a collaboration to build a multi-omics dataset focused on metabolic disorders in Asian populations. The partnership involves recruiting patients with chronic metabolic diseases for data collection, which will be used to develop AI-driven precision therapeutic and diagnostic solutions. This initiative aims to address the historical underrepresentation of Asian populations in metabolic disease research.